Table 1. General characteristics of the women and outcomes of the 2 studies.
| Ouidah trial | STOPPAM | p value* | ||
| Number of women | 687 | 752 | ||
| Mean age, (years)# | 24.9 (5.5; 15–45) | 26.4 (SD = 6.1, range = 15–45) | <0.001 | |
| Parity n (%) | Primigravidae | 181 (18.2) | 137 (26.4) | |
| Multigravidae | 506 (81.8) | 615 (73.6) | <0.001 | |
| Education n (%) | No education | 307 (44.7) | 425 (56.5) | |
| Partial or complete primary | 259 (37.7) | 212 (28.2) | <0.001 | |
| Secondary | 121 (17.6) | 115 (15.3) | ||
| Weight before pregnancy n (%) | BMI†≥20 | 491 (72.1) | 474 (63.8) | |
| BMI<20 | 190 (27.9) | 269 (36.2) | 0.001 | |
| Bed net at enrollment n (%) | No | 209 (30.4) | 511 (68.1) | |
| Yes | 478 (69.6) | 239 (31.9) | <0.001 | |
| Total number of visits n (%) | ≥5 visits | 300 (43.7) | 593 (78.9) | |
| <5 visits | 387 (56.3) | 159 (21.1) | <0.001 | |
| Newborn sex n (%) | Male | 349 (50.9) | 387 (51.5) | |
| Female | 336 (49.1) | 365 (48.5) | 0.85 | |
| Low birth weight n (%) | No | 628 (91.4) | 672 (89.4) | |
| Yes | 59 (8.6) | 80 (10.6) | 0.19 | |
| Mean weight at delivery (g)# | 3037.1 (429.6; 1350–4434) | 3008.23 (SD = 474.1; range = 1250–4850) | 0.23 | |
| Placental infection n (%) | No | 583 (95.9) | 579 (88.7) | |
| Yes | 25 (4.1) | 74 (11.3) | <0.001 | |
| Interval time between the last menstruation period and the first intake, days (SD) | 159.6 (23.3) | 144.7 (21.5) | <0.001 | |
| First SP dose intake timing n (%) | 6–7 months of gestation | 287 (41.8) | 120 (15.9) | |
| 5 months of gestation | 277 (40.3) | 357 (47.5) | ||
| 4 months of gestation | 123 (17.9) | 275 (36.6) | ||
| Interval time between the 2 doses, days (SD) | 60.3 (23.1) | 35.4 (9.9) | <0.001 |
#
mean, (Standard deviation (SD); range).
*
Differences between the 2 studies in proportions and means were compared using the χ2 and the Student t-test, respectively.
†
Body mass index.